Literature DB >> 22824485

Management of nonalcoholic steatohepatitis: an evidence-based approach.

Suzanne E Mahady1, Jacob George.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) and its progressive form, nonalcoholic steatohepatitis (NASH), are an increasingly common cause of chronic liver disease in the developed world, with NASH projected to be the leading cause of liver transplantation in the United States by 2020. This review of NASH management addresses current data from the perspective of levels of evidence for therapeutic options in NASH, including lifestyle modification, drug therapies, and bariatric surgery. In particular, behavioral therapies to assist patients in adopting lifestyle changes are highlighted and a research agenda for future NASH management is presented.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22824485     DOI： 10.1016/j.cld.2012.05.003

Source DB:  PubMed          Journal:  Clin Liver Dis        ISSN： 1089-3261            Impact factor:   6.126


  24 in total

1.  Genetic and hormonal control of hepatic steatosis in female and male mice.

Authors:  Frode Norheim; Simon T Hui; Emre Kulahcioglu; Margarete Mehrabian; Rita M Cantor; Calvin Pan; Brian W Parks; Aldons J Lusis
Journal:  J Lipid Res       Date:  2016-11-03       Impact factor: 5.922

2.  Ghrelin: a new treatment for non-alcoholic fatty liver disease?

Authors:  Patric J D Delhanty; Aart J van der Lely
Journal:  Endocrine       Date:  2012-09-20       Impact factor: 3.633

3.  Thymoquinone alleviates nonalcoholic fatty liver disease in rats via suppression of oxidative stress, inflammation, apoptosis.

Authors:  Azza S M Awad; Ekram N Abd Al Haleem; Wesam M El-Bakly; Mohie A Sherief
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-01-12       Impact factor: 3.000

4.  Therapies for nonalcoholic steatohepatitis.

Authors:  Suzanne Mahady
Journal:  Gastroenterol Hepatol (N Y)       Date:  2013-01

5.  Effect of a Low Glycemic Index Mediterranean Diet on Non-Alcoholic Fatty Liver Disease. A Randomized Controlled Clinici Trial.

Authors:  G Misciagna; M Del Pilar Díaz; D V Caramia; C Bonfiglio; I Franco; M R Noviello; M Chiloiro; D I Abbrescia; A Mirizzi; M Tanzi; M G Caruso; M Correale; R Reddavide; R Inguaggiato; A M Cisternino; A R Osella
Journal:  J Nutr Health Aging       Date:  2017       Impact factor: 4.075

6.  Monitoring acute metabolic changes in the liver and kidneys induced by fructose and glucose using hyperpolarized [2-13 C]dihydroxyacetone.

Authors:  Irene Marco-Rius; Cornelius von Morze; Renuka Sriram; Peng Cao; Gene-Yuan Chang; Eugene Milshteyn; Robert A Bok; Michael A Ohliger; David Pearce; John Kurhanewicz; Peder E Z Larson; Daniel B Vigneron; Matthew Merritt
Journal:  Magn Reson Med       Date:  2016-11-17       Impact factor: 4.668

7.  NLRP3 inflammasome activation is required for fibrosis development in NAFLD.

Authors:  Alexander Wree; Matthew D McGeough; Carla A Peña; Martin Schlattjan; Hongying Li; Maria Eugenia Inzaugarat; Karen Messer; Ali Canbay; Hal M Hoffman; Ariel E Feldstein
Journal:  J Mol Med (Berl)       Date:  2014-05-28       Impact factor: 4.599

8.  Adipose tissue-liver crosstalk during pathologic changes caused by vinyl chloride metabolites in mice.

Authors:  Brenna R Kaelin; Collin M McKenzie; Karl W Hempel; Anna L Lang; Gavin E Arteel; Juliane I Beier
Journal:  Toxicol Appl Pharmacol       Date:  2020-05-20       Impact factor: 4.219

Review 9.  From NAFLD to NASH to cirrhosis-new insights into disease mechanisms.

Authors:  Alexander Wree; Lori Broderick; Ali Canbay; Hal M Hoffman; Ariel E Feldstein
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-08-20       Impact factor: 46.802

10.  Loss of Junctional Adhesion Molecule A Promotes Severe Steatohepatitis in Mice on a Diet High in Saturated Fat, Fructose, and Cholesterol.

Authors:  Khalidur Rahman; Chirayu Desai; Smita S Iyer; Natalie E Thorn; Pradeep Kumar; Yunshan Liu; Tekla Smith; Andrew S Neish; Hongliang Li; Shiyun Tan; Pengbo Wu; Xiaoxiong Liu; Yuanjie Yu; Alton B Farris; Asma Nusrat; Charles A Parkos; Frank A Anania
Journal:  Gastroenterology       Date:  2016-06-21       Impact factor: 22.682
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.